Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Exp Neurol. 2020 Mar 3;328:113272. doi: 10.1016/j.expneurol.2020.113272

Figure 17. PBML CD11d expression in untreated HIV+ patient vs. HIV− control.

Figure 17.

Comparative FACS gated color dot plots for cryopreserved PBMLs from HIV+ cART-naïve patient and age- and sex-matched HIV− control show increased relative expression of CD16+, CD16+ CCR5+ CD14+ monocytes in the HIV+ patient with 100% of CD14+ CD16+ CCR5+ cells being CD11d+ in both the patient and HICV control. Upper panels indicate HIV+ patient data while lower panels represent the HIV− control data, with the numbers showing % of the indicated subpopulation in each panel. These data suggest the HIV effector cell, CD14+ CD16+ monocytes may utilize CD11d integrin for leukocyte trafficking downstream of CCR5.